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Abstract
Background: In order to better understand respiratory syncytial virus (RSV) epidemiology and burden in tropical
Africa, optimal case definitions for detection of RSV cases need to be identified.
Methods: We used data collected between September 2009 - August 2013 from children aged <5 years hospitalized
with acute respiratory Illness at Siaya County Referral Hospital. We evaluated the sensitivity, specificity, positive
predictive value (PPV) and negative predictive value (NPV) of individual signs, symptoms and standard respiratory
disease case definitions (severe acute respiratory illness [SARI]; hospitalized influenza-like illness [hILI]; integrated
management of childhood illness [IMCI] pneumonia) to detect laboratory-confirmed RSV infection. We also evaluated
an alternative case definition of cough or difficulty breathing plus hypoxia, in-drawing, or wheeze.
Results: Among 4714 children hospitalized with ARI, 3810 (81 %) were tested for RSV; and 470 (12 %) were positive.
Among individual signs and symptoms, cough alone had the highest sensitivity to detect laboratory-confirmed RSV
[96 %, 95 % CI (95–98)]. Hypoxia, wheezing, stridor, nasal flaring and chest wall in-drawing had sensitivities ranging
from 8 to 31 %, but had specificities >75 %. Of the standard respiratory case definitions, SARI had the highest sensitivity
[83 %, 95 % CI (79–86)] whereas IMCI severe pneumonia had the highest specificity [91 %, 95 % CI (90–92)]. The
alternative case definition (cough or difficulty breathing plus hypoxia, in-drawing, or wheeze) had a sensitivity of
[55 %, 95 % CI (50–59)] and a specificity of [60 %, 95 % CI (59–62)]. The PPV for all case definitions and individual
signs/symptoms ranged from 11 to 20 % while the negative predictive values were >87 %. When we stratified by
age <1 year and 1- < 5 years, difficulty breathing, severe pneumonia and the alternative case definition were more
sensitive in children aged <1 year [70 % vs. 54 %, p < 0.01], [19 % vs. 11 %, p = 0.01] and [66 % vs. 43 %, p < 0.01]
respectively, while non-severe pneumonia was more sensitive [14 % vs. 26 %, p < 0.01] among children aged 1- < 5 years.
Conclusion: The sensitivity and specificity of different commonly used case definitions for detecting laboratory-confirmed
RSV cases varied widely, while the positive predictive value was consistently low. Optimal choice of case definition will
depend upon study context and research objectives.
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Background
Respiratory syncytial virus (RSV) is a leading viral cause
of lower respiratory tract infection in infants and young
children, and an important cause of neonatal death in
Kenya [1–9] and worldwide [10–12]. Testing for RSV is
not routinely performed in resource-poor settings, and
the utility of clinical case definitions for measuring RSV
disease in these contexts is not well described. In Kenya,
case definitions designed for other purposes, such as for
influenza surveillance, have been used to estimate RSV
burden [7, 9]. However, the most sensitive and or spe-
cific clinical case definitions for detection of RSV among
patients with respiratory illness remain underexplored.
In addition, with candidate RSV vaccines in development
[2, 13], studies are needed to fully assess RSV disease
burden and standardized RSV case definitions will be
needed to evaluate vaccine efficacy and impact. An un-
derstanding of the performance of different clinical case
definitions for identifying RSV infection can guide re-
search and surveillance methodology.
We used data collected between September 2009 -
August 2013 from children aged <5 years hospitalized
with any respiratory illness at Siaya County Referral
Hospital. We evaluated the sensitivity, specificity, posi-
tive predictive value (PPV) and negative predictive value
(NPV) of individual respiratory signs, symptoms and
case definitions used for respiratory disease surveillance,
including severe acute respiratory infection (SARI),
Integrated Management of Childhood Illness (IMCI)
non-severe, severe and very severe pneumonia and a
hospitalized influenza like illness (hILI) case definition
to detect laboratory-confirmed RSV infections.
Methods
Study site and population
The Kenya Medical Research Institute, in partnership with
the U.S Centers for Disease Control and Prevention
(KEMRI/CDC), has conducted surveillance for hospitalized
acute respiratory illness (ARI) at Siaya County Referral
Hospital (SCRH) since August 2009. SCRH is an inpatient
facility with a bed capacity of 200, located in Karemo
Division, Siaya County, in Western Kenya. The population
is culturally homogenous and almost entirely rural [14].
The area is endemic for malaria [15] with a high under five
mortality ratio (94 deaths per 1000 live births in 2012,
KEMRI/CDC unpublished data) and a high HIV preva-
lence, estimated at 25.3 % among women aged ≥15 years
in Siaya County [16]. Antiretroviral treatment is recom-
mended for all HIV-infected children <10 years, and cover-
age among children in Siaya is estimated to be 43 % [16].
Data collection and management
Hospitalized acute respiratory infection (ARI) was broadly
defined as hospitalization with cough or difficulty
breathing or chest pain with an onset within the last
14 days. All children meeting the ARI case definition and
whose parents/guardians provided consent were enrolled
into the surveillance by trained study staff (nurses and
clinical officers). Demographic, clinical, and physical
examination data were collected using a structured ques-
tionnaire. Axillary temperatures were measured. Data pro-
cessing and management procedures for this surveillance
system have been described previously [17, 18].
Specimen collection and laboratory
Nasopharyngeal (NP) and oropharyngeal (OP) swabs
were collected from enrolled patients using flexible
mini-tip flocked swabs, then combined into a single vial
containing viral transport media. The samples were
transported at 4 °C and once received in the laboratory
were stored at −80 °C until testing. The cold chain was
maintained throughout the testing procedure. Nucleic
acids were extracted from the combined NP/OP swab
specimens, using a MagMax viral RNA kit and Kingfisher
mL instrument (Life Technologies, New York, NY). The
extracted nucleic acids were tested in a 1-step real-time
reverse-transcription polymerase chain reaction (RT-PCR)
assay with pathogen specific primers and probes, using
the AgPath-ID One-step RT-PCR kit (Applied Biosystems,
Foster City, CA) for RSV and other viruses. RSV was de-
tected using a fluorescence labelled hydrolysis/Taqman
probe at a final concentration of 0.1 μM, and the assay
was considered positive for RSV when exponential fluor-
escence curves crossed the assigned threshold at a thresh-
old cycle value of < 40.0 [9].
Data analysis
We analysed data on children aged <5 years hospitalized
with ARI at SCRH from September 2009 through
August 2013. Age specific cut-offs were used to define
tachypnea: respiratory rate ≥60 breaths per minute in
children <2 months, ≥50 breaths per minute in children
2–11 months, ≥40 breaths per minute for children aged
1- < 5 years [19]. Hypoxia was defined as oxygen satur-
ation <90 % on room air [19].
Standard World Health Organization case definitions
were used to classify ARI cases that met the criteria for
severe acute respiratory infection (SARI, based on 2013
definition [20]), and very severe, severe and non-severe
pneumonia according to the Integrated Management of
Childhood Illness (IMCI) guidelines [19]. We also
applied an influenza-like illness case definition (hILI,
normally used in outpatient settings) to hospitalized
patients [20], (Table 1). We further developed an alter-
native case definition by including all individual signs
and symptoms in a logistic regression model. We forced
the inclusion of cough and difficulty breathing into the
model and used stepwise selection to identify important
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covariates. The resulting case definition was defined as
cough or difficulty breathing plus any of hypoxia, chest
in-drawing or wheezing.
For each respiratory sign, symptom or case definition,
we calculated the risk ratio (RR) and 95 % confidence
interval to evaluate their association with laboratory-
confirmed RSV, and then evaluated the sensitivity, specifi-
city, PPV and NPV for detection of laboratory-confirmed
RSV infections. Case definition performance characteris-
tics were calculated for all children aged <5 years, then
stratified into two age groups (Infants aged <1 year and
children aged 1- < 5 years). We also stratified our results
by RSV peak and low season; RSV peak season was de-
fined as the months with average RSV prevalence above
10 %, these were April, May, June and July. Cumulative
sensitivities and specificities of the SARI, non-severe, se-
vere and very severe IMCI pneumonia, and hILI case defi-
nitions were calculated for increasing symptom durations
(days 1 to 14 after first symptom onset). For the case defi-
nitions, symptom duration was defined as the number of
days from the earliest onset of cough, difficulty breathing,
or fever to specimen collection.
We described demographic characteristics and labora-
tory outcomes of patients using proportions and means.
Proportions were compared across groups using z-test
for proportions whereas t-tests were used to compare
means of continuous variables. Associations between
categorical variables were assessed using chi square test
of independence. Tests with p-value < 0.05 were consid-
ered statistically significant. Analysis was performed
using SAS (version 9.2, Cary, NC).
Results
During September 2009 −August 2013, a total of 4714
children aged <5 years were hospitalized with an ARI. Of
these, 3878 (82.3 %) had NP/OP swabs collected; reasons
for non-collection (n = 836) included refusal (n = 464,
55.5 %), death before sample collection (n = 156, 18.7 %),
transfer to other facilities before sample collection (n = 30,
3.6 %), too ill to have sample collected (n = 22, 2.6 %), and
other (n = 164, 19.6 %). Among the 3878 with swabs
collected, 3810 (98.3 %) had RSV test results available; the
remaining 68 (1.7 %) were not tested in the laboratory
because the vials were either open or the transport media
volume did not meet the required threshold. RSV was
detected in 470 (12.3 %) of the children tested.
The mean age and oxygen saturation was similar be-
tween those tested and untested for RSV, (mean age
1.4 years vs. 1.4 years, p = 0.99) and (mean oxygen satur-
ation 93.7 vs. 93.4, p = 0.26) respectively. Of those tested
for RSV, 54.0 % were males compared to 58.0 % of the
untested (p = 0.03). Approximately 3 % (103/3810) of
those tested for RSV died compared to 19.6 % (177/904)
of ARI cases not tested for RSV (p < 0.01), (Table 2).
Slightly more than half 238 (50.6 %) of RSV-positive
cases were aged <1 year, (Table 3) and more than
three-quarters of all cases were aged <2 years, 360
(76.6 %). Cough, difficulty breathing, night sweats,
Table 1 Case definitions
Case definition All age groups
SARI An Acute Respiratory Infection with:
• History of fever or Measured fever of ≥38 °C
• And cough
• With an onset within the last 10 days
• And requires hospitalization
IMCI non-severe
pneumoniaa
Cough or difficulty breathing with fast
breathing.
- Fast breathing
• <2 months≥ 60 breaths/minute
• 2- > 12 months-≥ 50breaths/min
• 12–59 months- ≥ 40 breaths/min
IMCI severe
pneumoniab




Cough or difficulty breathing with any
one of:
- Stridor when calm





Hospitalized ILI A hospitalized Acute Respiratory Infection with:
• Measured fever of ≥38 °C
• And cough
• With an onset within the last 10 days
aExcludes those with chest in-drawing and those with danger signs (stridor,
unable to drink/breastfeed, convulsions, lethargy, unconsciousness and
vomit everything)
bExcludes those with danger signs
Table 2 Demographic and clinical characteristics of patients






n (%) n (%)
Patient characteristics
Age (n = 3810) (n = 904)
< 1 years 1756(46.1) 418(46.2) 0.94
1- < 5 years 2054(53.9) 486(53.8)
Mean age (years)a 1.4(1.1) 1.4(1.1) 0.99
Gender (n = 3810) (n = 904)
Male 2056(54.0) 524(58.0) 0.03
Illness Severity
Death (n = 3810) (n = 904)
Discharged dead 103(2.7) 177(19.6) <0.01
Oxygen saturation (n = 3796) (n = 900)
< 90 % 628(16.5) 157(17.4) 0.52
Mean Oxygen saturationa 93.7(6.8) 93.4(7.6) 0.26
aMean(sd) for the continuous variables
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hypoxia, wheezing, stridor, nasal flaring and chest wall
in-drawing were significantly associated with having a
laboratory-confirmed RSV infection, (Table 3). The
symptom/sign most strongly associated with RSV was
cough (RR, 2.56; 95 % CI, 1.60-4.10), (Table 3). The
presence of fever (measured or reported) was not as-
sociated with RSV infection.
Among the respiratory signs and symptoms examined,
cough alone had the highest sensitivity for laboratory
confirmed RSV (96.4 %, 95 % CI 94.7-98.1), followed by
night sweats, difficulty breathing and tachypnea; (71.7 %,
95 % CI 67.6-75.8), (61.9 %, 95 % CI 57.5-66.3) and
(61.3 %, 95 % CI 56.9-65.7) respectively. The other indi-
vidual signs and symptoms evaluated had sensitivities
that ranged from 8–31 %, (Table 4). The presence of
hypoxia, wheezing, stridor, nasal flaring and chest wall
in-drawing all had specificities >77 % for laboratory con-
firmed RSV (Table 4).
The standard respiratory case definition with the highest
sensitivity for detecting RSV infection was SARI (82.8 %,
Table 3 Demographic characteristics, signs, symptoms and case definitions associated with laboratory confirmed RSV infections
RSV + ve RSV -ve Crude RR p-value
n = 470 n = 3340 (95 % CI)
Demographic characteristics n % n %
Age group
< 1 year 238 50.6 1518 45.4 Ref
1- < 5 years 232 49.4 1822 54.6 0.83(0.70,0.99) 0.03
Sex
Male 254 54.0 1802 54.0 Ref
Female 216 46.0 1538 46.0 1.00(0.84,1.18) 0.97
HIV status
Positive 24 5.1 152 4.6 Ref
Negative 240 51.1 1728 51.7 0.89(0.61,1.32) 0.57
Unknown 206 43.8 1460 43.7 0.91(0.61,1.34) 0.63
Sign, symptoms and case definitions
Any fever 424 90.2 2984 89.3 1.09(0.82,1.45) 0.56
Measured fever ≥38 °C 126 26.8 797 23.9 1.15(0.95,1.39) 0.16
Reported fever 418 88.9 2957 88.5 1.04(0.79,1.36) 0.8
Cough 453 96.4 3023 90.5 2.56(1.60,4.10) <0.01
Difficulty breathing 291 61.9 1715 51.3 1.46(1.23,1.74) <0.01
Chest pain 1 0.2 23 0.7 0.34(0.05,2.30) 0.27
Night sweats 337 71.7 2224 66.6 1.24(1.02,1.49) 0.03
Tachypneaa 288 61.3 1948 58.3 1.11(0.94,1.33) 0.22
Hypoxiab 121 26.2 507 15.6 1.76(1.46,2.12) <0.01
Wheeze 125 26.6 569 17.0 1.63(1.35,1.96) <0.01
Stridor 36 7.7 142 4.3 1.69(1.25,2.30) <0.01
Nasal flaring 146 31.1 739 22.1 1.49(1.24,1.78) <0.01
Chest In-drawing 145 30.9 699 20.9 1.57(1.31,1.88) <0.01
SARI 389 82.8 2579 77.2 1.36(1.09,1.71) 0.01
ILI 112 23.8 678 20.3 1.20(0.98,1.46) 0.08
IMCI Non-severe pneumonia 95 20.2 777 23.3 0.85(0.69,1.06) 0.14
IMCI severe pneumonia 71 15.1 310 9.3 1.60(1.27,2.01) <0.01
IMCI very severe pneumonia 236 50.2 1719 51.5 0.96(0.81,1.13) 0.61
Cough or difficulty breathing plus hypoxia,
chest in-drawing or wheeze
257 54.7 1316 39.4 1.72(1.15,2.03) <0.01
aDefined as respiratory rate ≥60 breaths per minute in kids <2 months, ≥50 breaths per minute in kids 2–11 months, ≥40 breaths per minute for kids 1- < 5 years
bDefined as oxygen saturation <90 % on room air. 14/3810 missing oxygen saturation
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95 % CI 79.4-86.2), followed by IMCI very severe pneumo-
nia (50.2 %, 95 % CI 45.7-54.7), (Table 4. Fig. 1). The sensi-
tivities for IMCI non-severe pneumonia, IMCI severe
pneumonia and hILI were lower; (20.2 %, 95 % CI
16.6-23.8), (15.1 %, 95 % CI 11.9-18.3) and (23.8 %,
95 % CI 20.0-27.7) respectively. The highest specificity
was observed in IMCI severe pneumonia (90.7 %, 95 % CI
89.7-91.7), closely followed by hILI and IMCI non-severe
pneumonia definitions; (79.7 %, 95 % CI 78.3-81.1) and
(76.7 %, 95 % CI 75.3-78.2) respectively. SARI and IMCI
Table 4 Sensitivity, specificity, PPV and NPV of signs, symptoms and case definitions












All under 5 n % n %
Cough 453 96.4 3023 90.5 96.4(94.7,98.1) 9.5(8.5,10.5) 13.0(11.9,14.2) 94.9(92.6,97.3)
Difficulty breathing 291 61.9 1715 51.3 61.9(57.5,66.3) 48.7(47.0,50.4) 14.5(13.0,16.1) 90.1(88.7,91.5)
Night sweats 337 71.7 2224 66.6 71.7(67.6,75.8) 33.4(31.8,35.0) 13.2(11.9,14.5) 89.4(87.6,91.1)
Tachypnea 288 61.3 1948 58.3 61.3(56.9,65.7) 41.7(40.0,43.4) 12.9(11.5,14.3) 88.4(86.9,90.0)
Hypoxia 121 25.9 507 15.2 25.9(21.9,29.8) 84.8(83.5,86.0) 19.3(16.2,22.4) 89.1(88.0,90.1)
Wheeze 125 26.6 569 17.0 26.6(22.6,30.6) 83.0(81.7,84.2) 18.0(15.2,20.9) 88.9(87.8,90.0)
Stridor 36 7.7 142 4.3 7.7(5.3,10.1) 95.8(95.1,96.4) 20.2(14.3,26.1) 88.1(87.0,89.1)
Nasal flaring 146 31.1 739 22.1 31.1(26.9,35.3) 77.9(76.5,79.3) 16.5(14.1,18.9) 88.9(87.8,90.1)
Chest In-drawing 145 30.9 699 20.9 30.9(26.7,35.0) 79.1(77.7,80.5) 17.2(14.6,19.7) 89.0(87.9,90.2)
SARI 389 82.8 2579 77.2 82.8(79.4,86.2) 22.8(21.4,24.2) 13.1(11.9,14.3) 90.4(88.4,92.4)
hILI 112 23.8 678 20.3 23.8(20.0,27.7) 79.7(78.3,81.1) 14.2(11.7,16.6) 88.2(87.0,89.3)
IMCI Non-severe pneumonia 95 20.2 777 23.3 20.2(16.6,23.8) 76.7(75.3,78.2) 10.9(8.8,13.0) 87.2(86.0,88.4)
IMCI severe pneumonia 71 15.1 310 9.3 15.1(11.9,18.3) 90.7(89.7,91.7) 18.6(14.7,22.6) 88.4(87.3,89.4)
IMCI very severe pneumonia 236 50.2 1719 51.5 50.2(45.7,54.7) 48.5(46.8,50.2) 12.1(10.6,13.5) 87.4(85.9,88.9)
Cough or difficulty breathing plus
hypoxia, chest in-drawing or wheeze




Cough 232 97.5 1373 90.4 97.5(95.5,99.5) 9.6(8.1,11.0) 14.5(12.7,16.2) 96.0(92.9,99.1)
Difficulty breathing 166 69.8 863 56.8 69.8(63.9,75.6)a 43.2(40.7,45.6)a 16.1(13.9,18.4) 90.1(87.9,92.3)
SARI 189 79.4 1175 77.4 79.4(74.3,84.6) 22.6(20.5,24.7) 13.9(12.0,15.7) 87.5(84.2,90.8)
hILI 52 21.9 307 20.2 21.9(16.6,27.1) 79.8(77.8,81.8) 14.5(10.8,18.1) 86.7(84.9,89.5)
IMCI Non-severe pneumonia 34 14.3 312 20.6 14.3(9.8,18.7)a 79.5(77.4,81.5)a 9.8(6.7,13.0) 85.5(83.7,87.4)
IMCI severe pneumonia 46 19.3 175 11.5 19.3(14.3,24.3)a 88.5(86.9,90.1)a 20.8(15.5,26.2) 87.5(85.8,89.2)
IMCI very severe pneumonia 117 49.2 726 47.8 49.2(42.8,55.5) 52.2(49.7,54.7) 13.9(11.6,16.2) 86.8(84.6,89.0)
Cough or difficulty breathing plus
hypoxia, chest in-drawing or wheeze
157 66.0 698 46.0 66.0(60.0,72.0)a 54.0(51.5,56.5)a 18.4(15.8,21.0) 91.0(89.1,92.9)
Children
1- < 5 years
n 232 1822
Cough 221 95.3 1650 90.6 95.3(92.5,98.0) 9.4(8.1,10.8) 11.8(10.4,13.3) 94.0(90.6,97.4)
Difficulty breathing 125 53.9 852 46.8 53.9(47.5,60.3)a 53.2(51.0,55.5)a 12.8(10.7,14.9) 90.0(88.3,91.9)
SARI 200 86.2 1404 77.1 86.2(81.8,90.6) 22.9(21.0,24.9) 12.5(10.9,14.1) 92.9(90.5,95.3)
hILI 60 25.9 371 20.4 25.9(20.2,31.5) 79.6(77.8,81.5) 13.9(10.7,17.2) 89.4(87.9,90.9)
IMCI Non-severe pneumonia 61 26.3 465 25.5 26.3(20.6,32.0)a 74.5(72.5,76.5)a 11.6(8.9,14.3) 88.8(87.2,90.4)
IMCI severe pneumonia 25 10.8 135 7.4 10.8(6.8,14.8)a 92.6(91.4,93.8)a 15.6(10.0,21.3) 89.1(87.7,90.5)
IMCI very severe pneumonia 119 51.3 993 54.5 51.3(44.9,57.7) 45.5(43.2,47.8) 10.7(8.9,12.5) 88.0(85.9,90.1)
Cough or difficulty breathing plus
hypoxia, chest in-drawing or wheeze
100 43.1 618 33.9 43.1(36.7,495)a 66.1(63.9,68.3)a 13.9(11.4,16.5) 90.1(88.5,91.7)
aSensitivity and specificity significantly different between the two age groups
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very severe pneumonia had specificities of 22.8 % (95 % CI
21.4-24.2) and 48.5 % (95 % CI 46.8-50.2), respectively.
The alternative case definition developed through logistic
regression; cough or difficulty breathing plus hypoxia,
chest in-drawing, or wheeze had a sensitivity and specifi-
city of (54.7 %, 95 % CI 50.2-59.2) and (60.1 %, 95 % CI
58.9-62.3) respectively. We plotted a receiver operator
characteristics chart for these case definitions, (Fig. 1).
The PPV for all case definitions, signs and symptoms
assessed ranged between 11–20 % whereas the negative
predictive values were >87 %, (Table 4).
When stratified by age group, SARI continued to be
the most sensitive case definition (79.4 % sensitive in in-
fants aged <1 year and 86.2 % sensitive in children aged
1- < 5 years), and IMCI severe pneumonia was the most
specific (88.5 % in infants aged <1 year and 92.6 % in
children aged 1- < 5 years). Comparing across age
groups, IMCI severe pneumonia was significantly more
sensitive (19.3 % vs. 10.8 %, p = 0.01) and less specific
(88.5 % vs. 92.6 %, p < 0.01) among those aged <1 year
compared to children aged 1- < 5 years (Table 4). Cough
or difficulty breathing plus hypoxia, chest in-drawing or
wheeze was also significantly more sensitive (66.0 % vs.
43.1 %, p < 0.01) and less specific (54.0 % vs. 66.1 %,
p < 0.01) among the younger age group. Difficulty breath-
ing was also significantly more sensitive (69.8 % vs. 53.9 %,
p < 0.01) and less specific (43.2 % vs. 53.2 %, p < 0.01)
among the younger age group. IMCI non-severe pneu-
monia was significantly less sensitive (14.3 % vs.
26.3 %, p < 0.01) and more specific (79.5 % vs. 74.5 %,
p < 0.01) among infants aged <1 year compared to chil-
dren aged 1- < 5 years, (Table 4). There was no significant
difference in sensitivity, specificity and predictive values
for the other case definitions between the <1 and 1- < 5
age groups. When we stratified by season, we observed
significant difference in the PPVs for all signs, symptoms
and case definitions evaluated, with significantly higher
PPVs in the RSV peak season, (Table 5). There was no sta-
tistically significant difference in the sensitivities and spec-
ificities of the case definitions by number of days from
symptom onset, (Figs. 2 and 3) except for SARI where spe-
cificity decreased from day 1 to 3 (46.2–25.4 %, p < 0.01)
then stabilized, (Fig. 3).
Discussion
We observed wide variations in the sensitivity and
specificity of the signs, symptoms and case definitions
evaluated. SARI, a case definition requiring cough and
either reported or measured fever and developed for
global influenza surveillance was the most sensitive case
definition for RSV detection with sensitivity of 83 %.
The most specific case definition was IMCI severe
pneumonia (cough or difficulty breathing plus chest in-
drawing). Generally there was a trade-off between sensi-
tivity and specificity. Cough or difficulty breathing plus
hypoxia, chest in-drawing or wheeze provided the best
balance; it was the only case definition for which both
sensitivity and specificity exceeded 50 %. The predictive
values were more consistent across case definitions, with
all having relatively low PPV (11–20 %) and high NPV
(87–90 %).
In determining the optimal case definition, consider-
ation should be given to the context in which the case
definition applies and the objectives for which it is being
used. If the primary objective of the study is to estimate
the burden of RSV disease then it is important to use a
Fig. 1 Receiver operator characteristic (ROC) chart for case definitions
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case definition offering high sensitivity. We found that
cough alone had the highest sensitivity (96 %) to detect
RSV. If the goal was to detect the maximum number of
RSV cases then cough alone might be the best definition
to use. However, using cough alone would also give very
many false positives (PPV 13 %). Of the case definitions
evaluated we found that the 2013 WHO SARI case def-
inition was most sensitive for RSV detection. Nonethe-
less, the SARI case definition may miss up to 17 % of
RSV cases. Much of what is known about RSV globally
comes from surveillance systems that utilize case defini-
tions intended for other diseases (e.g. influenza, pneu-
monia) that are not optimized for detection of RSV, the
potential for underestimation should therefore be recog-
nized in interpreting data on RSV burden, particularly if
using a case definition that requires measured fever (e.g.
hILI) or includes only pneumonia without danger signs
(e.g. IMCI non-severe or severe pneumonia).
Sometimes maximum specificity is desired for RSV de-
tection. If RSV vaccines currently under development are
eventually introduced into routine immunization pro-
grams there will be a need to evaluate the impact and
effectiveness of the vaccine. Given that RSV testing is not
widely available in resource poor settings, a clinical case
definition may be most practical for use in vaccine evalua-
tions such as case–control vaccine effectiveness studies or
analyses of trends in disease burden. For this purpose, a
highly specific case definition is preferable [21, 22]. We
found that the presence of stridor offered the highest spe-
cificity (96 %). However, it was present in < 8 % of cases,
and therefore not easily embraceable as a case definition.
Among the case definitions evaluated, we found that IMCI
severe pneumonia was the most specific (91 %), while hILI
and non-severe pneumonia case definitions also provided
reasonable specificity (77–80 %). Measuring vaccine im-
pact and effectiveness using the IMCI severe pneumonia
case definitions may be more feasible than using less spe-
cific case definitions such as SARI. However, even if the
most specific case definition were used, most cases identi-
fied may not be RSV-infected because all the case defini-
tions were found to have poor PPV.











Difficulty in breathing 26.3(23.1,29.6) 83.8(81.0,86.7)
SARI 22.8(20.3,25.3) 83.2(78.9,87.5)
hILI 26.5(21.1,31.9) 79.7(77.3,82.1)
IMCI Non-severe pneumonia 19.8(15.1,24.5) 78.1(75.6,80.5)
IMCI severe pneumonia 35.4(27.6,43.2) 80.2(77.9,82.4)
IMCI very severe pneumonia 19.9(16.9,22.8) 76.6(73.3,79.9)
Cough or difficulty breathing






Difficulty in breathing 8.1(6.6,9.6) 93.5(92.1,94.9)
SARI 7.8(6.6,9.0) 94.2(92.2,96.2)
hILI 8.3(5.9,10.6) 92.9(91.8,94.1)
IMCI Non-severe pneumonia 6.8(4.8,8.9) 92.5(91.3,93.7)
IMCI severe pneumonia 8.4(4.9,12.0) 92.8(91.7,93.9)
IMCI very severe pneumonia 7.6(6.1,9.1) 92.9(91.5,94.3)
Cough or difficulty breathing
plus hypoxia, chest in-drawing
or wheeze
9.4(7.6,11.3) 94.1(92.9,95.3)
Fig. 2 Cumulative sensitivity of case definitions to detect Laboratory confirmed RSV
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We observed positive predictive values (PPVs) ranging
from 11–20 % for all signs, symptoms and case defini-
tions, though the PPVs were significantly higher during
periods of RSV circulation (cold months of the year in
Western Kenya; April through July). A case definition with
a high PPV is useful to investigators aiming to maximize
the detection of laboratory confirmed cases among those
tested. For example, studies focused on subtyping or se-
quencing for which the positive RSV isolate is essential
may benefit from a case definition with optimal PPV. In
this analysis, the case definition with the highest PPV for
detection of laboratory confirmed RSV was IMCI severe
pneumonia. However, even during peak RSV season,
roughly one in three children with IMCI severe pneumo-
nia will have a positive RSV test result.
Although the prevalence of RSV infection is generally
higher among infants hospitalized with respiratory
disease compared with older children hospitalized with
respiratory disease [1], we did not observe significant
differences in PPV when stratifying by age group. Diffi-
culty breathing, severe pneumonia and the alternative
definition were found to be more sensitive among the
infants aged <1 year, while IMCI non-severe pneumonia
was more sensitive among those aged 1- < 5 years. Older
children with RSV are likely to be experiencing a reinfec-
tion rather than a primary infection, and therefore may
present with milder illness [4]. These findings highlight
that choice of case definition for detecting RSV cases
should take into account the age group under surveillance.
We found that sensitivity, specificity and predictive
values for the case definitions to detect RSV infections
did not vary significantly with respect to duration from
illness onset to sample collection, suggesting that these
case definitions can be used within the 14-day period
from symptom onset to detect RSV infection without
concern about loss of sensitivity or specificity.
The presence of wheezing, hypoxia, stridor, nasal flar-
ing and chest wall in-drawing were each found to be sig-
nificantly associated with RSV infection. This finding is
similar to findings from Rarieda and Kilifi districts in
Kenya and Ballabgarh in northern India [1, 6, 9, 23] and
suggest that some of the individual IMCI danger signs
might be used to identify subsets of children more likely
to have RSV virus infections. It should however be noted
that there is some variation in the literature regarding
the association of hypoxia with RSV infections. Hypoxia
was found to be negatively associated with RSV infection
in one study conducted in Kilifi District, Kenya [1], with
another study reporting no significant association from
the same site [6]. We found that neither measured nor
reported fever were associated with RSV infection,
however history of fever was a common symptom ob-
served in nearly 90 % of children infected with RSV.
Fever was a common symptom in many RSV infected
patients in other studies as well [23–25] with one study
[6] observing that fever was significantly more common
among the RSV-infected children compared to children
with respiratory disease that tested negative for RSV,
RR = 1.54(95 % CI, 1.33–1.80). The high prevalence of
malaria in our study site [14, 15] may impact the ob-
served association between fever and RSV.
Interestingly, the performance of various case defini-
tions for detecting RSV infection that we observed in
this study differed substantially from the findings of a
study in Ballabgarh, northern India, for which all hospi-
talized children aged <5 years were tested for RSV [23].
While we found the SARI case definition to be the most
sensitive, and severe IMCI pneumonia to be most
Fig. 3 Cumulative specificity of case definitions to detect Laboratory confirmed RSV
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specific, that study reported SARI to have a low sen-
sitivity and IMCI pneumonia or severe pneumonia
(combined) to have a low specificity. Differences in
epidemiologic contexts (e.g. malaria or HIV prevalence)
may explain some of the variation in results. The precise
definitions used for SARI and IMCI pneumonia also dif-
fered across the two studies. Furthermore, the study
from India included all hospitalized children (regardless
of clinical signs), while our study included only children
hospitalized with cough or difficulty breathing or chest
pain. Of note, the Indian study found that restricting to
even a very broad respiratory case definition (acute onset
cough or sore throat or shortness of breath or coryza or
clinician judgement that illness due to infection) would
fail to detect 13.5 % (10/74) of RSV cases; thus our ana-
lysis likely failed to include some children hospitalized
with RSV infection.
In interpreting our results, the following additional
limitations should be taken into consideration. This ana-
lysis was restricted to inpatients; the findings therefore
may not be relevant for outpatient respiratory disease
surveillance. Furthermore, because non-severe IMCI
pneumonia is typically managed in the outpatient setting
in Kenya, those children with non-severe pneumonia in-
cluded in this analysis may be a somewhat biased group.
In addition, a substantial number of severe cases were
not swabbed and consequently excluded from this ana-
lysis; therefore these findings may not be representative
of the most severe spectrum of cases with RSV infection.
Lastly, RT-PCR was the only method used for RSV de-
tection in our surveillance system; therefore sensitivities
and specificities could vary in studies where other
methods such as culture or serology are used.
Conclusion
The optimal case definition for use in detecting RSV var-
ies depending upon context. Researchers must take into
account their objectives, available resources, and the
study population. For estimating the burden of RSV in a
context similar to Western Kenya, the WHO SARI case
definition could be used, particularly if it is already being
implemented in a sentinel influenza surveillance system.
However more specific case definitions may be required
for evaluating future RSV vaccines in settings where
diagnostic testing is not readily available. Additional re-
search to assess the performance of various case defini-
tions for detecting RSV infections across a broad range
of epidemiologic contexts is needed.
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